DAX25.261 +0,9%Est506.131 +1,2%MSCI World4.343 -0,1%Top 10 Crypto8,6000 +0,9%Nas22.814 +0,6%Bitcoin57.364 +0,9%Euro1,1758 -0,1%Öl71,90 -0,1%Gold5.066 +1,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 SAP 716460 NVIDIA 918422 Siemens Energy ENER6Y Deutsche Telekom 555750 Infineon 623100 Amazon 906866 Lufthansa 823212 Microsoft 870747 Airbus 938914 RENK RENK73 BASF BASF11 Siemens 723610 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht stärker ins Wochenende -- Supreme Court stoppt Trump-Zölle -- NVIDIA wohl mit Milliardeninvestment in OpenAI -- Apple, Telekom, BioNTech, Moderna, Diginex, Bayer, im Fokus
Top News
Infineon-Aktie heute Ex-Dividende: Bullishe Signale durch KI-Fokus Infineon-Aktie heute Ex-Dividende: Bullishe Signale durch KI-Fokus
Favoriten der Finanzprofis: Diese Aktien empfehlen Experten zu kaufen Favoriten der Finanzprofis: Diese Aktien empfehlen Experten zu kaufen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

UCB Aktie

Kaufen
Verkaufen
UCB Aktien-Sparplan
275,50 EUR -7,70 EUR -2,72 %
STU
278,70 EUR -7,10 EUR -2,48 %
GVIE
UCB jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.54,23 Mrd. EUR

KGV34,29Div. Rendite0,51%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN852738

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINBE0003739530

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolUCBJF

UCB Aktien News

DatumMeistgelesen
MotleyFoolUnited Community Banks UCB Earnings Transcript
PR NewswireUCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
PR NewswireUCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
Wer­bungUCB-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR Newswire/C O R R E C T I O N -- UCB/
PR NewswireU.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
PR NewswireUCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
PR NewswireUCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
PR NewswireBIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
PR NewswireResults published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
ZacksRecent Price Trend in UCB (UCBJY) is Your Friend, Here's Why
PR NewswireBIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
PR NewswireBIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
PR NewswireGen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
ZacksUCB (UCBJY) Is a Great Choice for 'Trend' Investors, Here's Why
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
ZacksAll You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy
ZacksHere's Why Momentum in UCB (UCBJY) Should Keep going
PR NewswireUCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
MotleyFoolUnited Community Banks UCB Earnings Transcript
ZacksUCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZacksHere's What Could Help UCB (UCBJY) Maintain Its Recent Price Strength
PR NewswireUCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
PR NewswireUCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
PR NewswireUCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
PR NewswireInaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
PR NewswireUCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
BenzingaBiogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
PR NewswireBIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
PR NewswireUCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
PR NewswireUCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
GlobeNewswireUCB Convening Notice to the General Meeting of the Shareholders 2025
PR NewswireNew data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
PR NewswireEpilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
PR NewswireBIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
PR NewswireBIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
PR NewswireOn Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
PR NewswireUCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

UCB News

UCB News: auf dieser Seite finden Sie alle UCB News und Nachrichten zur UCB Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch UCB News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um UCB News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.